Telomir Pharmaceuticals, Inc. Common Stock (TELO)

US — Healthcare Sector
Peers:

Automate Your Wheel Strategy on TELO

With Tiblio's Option Bot, you can configure your own wheel strategy including TELO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol TELO
  • Rev/Share 0.0
  • Book/Share -0.0054
  • PB -387.9533
  • Debt/Equity 0.0
  • CurrentRatio 0.753
  • ROIC 64.4675

 

  • MktCap 62501607.0
  • FreeCF/Share -0.1342
  • PFCF -15.6483
  • PE -4.993
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -20.0964

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation TELO Rodman & Renshaw -- Buy -- $15 Feb. 21, 2025

News

Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia
TELO
Published: May 07, 2025 by: Accesswire
Sentiment: Neutral

MIAMI, FLORIDA / ACCESS Newswire / May 7, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir"), a leader in age-reversal science, today announced new preclinical data showing that its lead oral drug candidate, Telomir-1, reverses multiple hallmarks of cellular decline across several human cell lines. The findings include improved mitochondrial activity, reduced oxidative stress, restored calcium balance, and protection from toxic metal effects-offering a mechanistic foundation for the Company's new research initiatives in autism spectrum disorder (ASD) and spasmodic dysphonia (SD).

Read More
image for news Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia
Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines
TELO
Published: February 26, 2025 by: Accesswire
Sentiment: Neutral

New Study Confirms Telomir-1 Also Reverses Oxidative Stress, Preserves Cellular Integrity, and Prevents Cell Death by Protecting Mitochondria-The Cell's Power Source and Gatekeeper of Life and Death MIAMI, FLORIDA / ACCESS Newswire / February 26, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir"), a leader in age-reversal science, today announced compelling new preclinical findings demonstrating that Telomir-1 fully reverses calcium dysregulation-an often-overlooked yet fundamental driver of cell death, aging, and disease progression-in multiple human cell lines." In addition to restoring calcium homeostasis, the study further confirmed that Telomir-1 reverses oxidative stress and provides robust cellular protection against stress-induced damage.

Read More
image for news Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines
Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market
TELO
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral

MIAMI, FLORIDA / ACCESS Newswire / February 21, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or Telomir, a leader in age-reversal science, today announced a breakthrough achievement-Telomir-1 has successfully captured and stabilized both Silver(I) (Ag⁺) and the highly reactive Silver(II) (Ag²⁺) in a biologically compatible form. This milestone overcomes a major limitation in silver-based medical applications, opening the door for advanced antimicrobial treatments, wound care solutions, and infection-resistant medical coatings.

Read More
image for news Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market
Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)
TELO
Published: February 18, 2025 by: Accesswire
Sentiment: Neutral

MIAMI, FLORIDA / ACCESS Newswire / February 18, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or Telomir, a leader in age-reversal science, today announced groundbreaking results from its recent preclinical studies conducted in human retinal cell lines. These studies demonstrated the ability of Telomir-1 to significantly reverse copper and iron-induced elevation of Reactive Oxygen Species (ROS).

Read More
image for news Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)

About Telomir Pharmaceuticals, Inc. Common Stock (TELO)

  • IPO Date 2019-04-09
  • Website https://telomirpharma.com
  • Industry Biotechnology
  • CEO Mr. Erez Aminov
  • Employees 1

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.